80635-97-8

Usage

Chemical Class

Pyridine class of organic compounds

Derivative

A derivative of pyridine, a heterocyclic aromatic ring with a nitrogen atom

Molecular Weight

199.29 g/mol

Usage

Commonly used as a building block in the synthesis of various pharmaceuticals and agrochemicals

Structure

A pyridine ring with a 4-methyl substituent and a 4-isopropylphenyl substituent

Additional Uses

Can be used as a ligand in coordination chemistry and as a reagent in organic synthesis.

InChI:InChI=1/C15H17N/c1-11(2)13-4-6-14(7-5-13)15-10-12(3)8-9-16-15/h4-11H,1-3H3

Upstream product

• 4926-28-7 2-Bromo-4-picoline 
• 16152-51-5 (4-isopropylphenyl)boronic acid 

Downstream Products

• 452343-07-6 2-[2-(4-isopropylphenyl)pyridin-4-yl]-1-(pyridin-2-yl)ethanone 
• 80635-66-1 6-(4-Isopropyl-phenyl)-4-methyl-pyridine-2-carboxylic acid (1H-tetrazol-5-yl)-amide 
• 80636-26-6 6-(4-Isopropyl-phenyl)-4-methyl-pyridine-2-carboxylic acid 

Relevant academic research and scientific papers

Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N- (tetrahydro-2H-pyran-4-yl)benzamide (GW788388): A potent, selective, and orally active transforming growth factor-β type I receptor inhibitor

Inhibitors of transforming growth factor β (TGF-β) type I receptor (ALK5) offer a novel approach for the treatment of fibrotic diseases such as renal, hepatic, and pulmonary fibrosis. The optimization of a novel phenylpyridine pyrazole series (1a) led to the identification of potent, selective, and orally active ALK5 inhibitors. The cellular potency and pharmacokinetics profiles of these derivatives were improved and several compounds presented antifibrotic activity when orally administered to rats in an acute liver model of dimethylnitrosamine- (DMN-) induced expression of collagen IA1 mRNA, a major gene contributing to excessive extra cellular matrix deposit. One of the most potent ALK5 inhibitors identified in this chemical series, compound 13d (GW788388), reduced the expression of collagen IA1 by 80% at a dose of 1 mg/kg twice a day (b.i.d.). This compound significantly reduced the expression of collagen IA1 mRNA when administered orally at 10 mg/kg once a day (u.i.d.) in a model of puromycin aminonucleoside-induced renal fibrosis.